Pricing Log in Create free account
Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue
+268.4%
EPS
+73.8%
Free cash flow
+81.1%
Total debt
+0.27%

Quarter to September 2026, against a year earlier

111.86 3.10 +2.85%
Market cap
$23.9B
P/E
0.0×
Fwd P/E
−64.6×
Dividend yield
—
F-score
4/9
Altman Z
9.29
Beneish M
−1.90
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Insmed, Inc. (INSM) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2026 P1I2: 7 added · 10 removed · 26 modified
P2I1A: no changes 		Short cash runway Receivables outpacing revenue
8-K Oct 16, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K Oct 5, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 18 added · 63 removed · 40 modified
P2I1A: no changes
8-K Jul 16, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 13, 2026 5.07 Submission of matters to a vote of security holders
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 7, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 23, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 57 added · 29 removed · 109 modified
1A: 32 added · 20 removed · 223 modified
7: 14 added · 16 removed · 45 modified
8-K Feb 17, 2026 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Jan 9, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 17, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 18, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K May 8, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Feb 18, 2025 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Oct 31, 2024 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K May 9, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 22, 2024 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.